Cerevel Therapeutics Holdings, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Interest income (expense), net
Interest income, net
Interest expense
Other income (expense), net (including related party amounts), (Notes 8, 11 and 20)
Loss before income taxes
Income tax benefit (provision), net
Net loss
Benefit related to the redemption of Series A-1 redeemable convertible preferred stock at less than the carrying value
Net loss attributable to common stockholders
Other comprehensive income (loss):
Changes in fair value attributable to instrument-specific credit risk (including related party amounts), (Notes 8, 10 and 20)
Unrealized gains (losses) on securities available-for-sale
Total other comprehensive income (loss)
Comprehensive loss
Net loss per share, basic
Net loss per share, diluted
Weighted-average shares used in calculating net loss per share, basic
Weighted-average shares used in calculating net loss per share, diluted

Comments